Why Choose AZ Regenerative Medicine
Hur KY, Lee MS
Since there are no effective treatments for dementia, many scientists focus their work on identifying what are called modifying factors , the conditions which can either increase or decrease a persons risk of developing, say, Alzheimers disease
A randomized Phase II clinical trial confirmed that the triple therapy combination of an anti-PD-1 antibody (Sintilimab), an HDAC inhibitor (Citarinostat), and an anti-VEGF antibody (Bevacizumab) demonstrated significant clinical efficacy in colorectal cancer
Key Questions to Ask Your Doctor About Dual-Therapy Weight Loss Before considering any combination approach, ask your physician whether semaglutide or tirzepatide monotherapy at an optimized dose meets your weight-loss goal
References Siegel RL, Miller KD, Jemal A